Animal models of atrial fibrillation (AFib) are currently available in dog and sheep. These models, however, require prolonged pacing at rapid rates to induce atrial fibrillation. This technology presents a mouse model of spontaneous and permanent atrial fibrillation at a young age. It does not require induction or pacing and significantly simplifies study protocols. Such a mouse model provides a low-cost and reliable means for the study of atrial fibrillation and the development of novel drug candidates targeting this therapeutic area.
While common, animal models typically used for the study of atrial fibrillation require prolonged induction or pacing at a rapid rate to induce AFib. The technology described herein provides a mouse model with permanent atrial fibrillation from a young age. Further, this technology develops spontaneous AFib without the need of induction or pacing. Compared to larger, more common, animal models, this technology provides the opportunity to reduce complexity in study protocols by eliminating induction or pacing, accelerating the turnaround time for preclinical studies, ultimately lowering costs for early drug development and increasing speed to market.
Spontaneous and permanent atrial fibrillation in this mouse model was confirmed via electrocardiogram.
Patent Pending
Tech Ventures Reference: IR CU14098